Beehive Botanicals consent decree approved
This article was originally published in The Rose Sheet
Executive Summary
The U.S. District Court for the Western District of Wisconsin enters a consent decree of condemnation and injunction against Beehive Botanicals, under which the manufacturer agrees to forfeit certain bee-derived materials to the Department of Justice. The Hayward, Wis., company had product seized this year after FDA found its website made drug claims via links to other sites for its products, including creams and shampoos (1"The Rose Sheet" April 12, 2010). The decree, entered by the court May 14, additionally requires Beehive Botanicals to hire a third-party expert to inspect its labeling and certify the corrections to FDA, according to a DoJ release
You may also be interested in...
FDA Stings Beehive Botanicals For Web Links That "Fell Through The Cracks"
Beehive Botanicals has endured product seizure, a complaint from FDA for making unapproved drug claims and potential damage to its reputation because it did not have a firm handle on all dimensions of its online business
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.